It has been shown in an adult mouse model of epilepsy that GLT-1 and GLAST immunoreactivity significantly increases in the first 3 days after intrahippocampal injection of kainate acid (NMDA-R analog). This evidence concerns the gene SLC1A2 and epilepsy.